Skip to Content
Discovering the causes of cancer and the means of prevention

Publications Search - Abstract View

Title: Prediagnostic transcriptomic markers of Chronic lymphocytic leukemia reveal perturbations 10 years before diagnosis.
Authors: Chadeau-Hyam M,  Vermeulen RC,  Hebels DG,  Castagné R,  Campanella G,  Portengen L,  Kelly RS,  Bergdahl IA,  Melin B,  Hallmans G,  Palli D,  Krogh V,  Tumino R,  Sacerdote C,  Panico S,  de Kok TM,  Smith MT,  Kleinjans JC,  Vineis P,  Kyrtopoulos SA,  EnviroGenoMarkers project consortium
Journal: Ann Oncol
Date: 2014 May
Branches: BB, OEEB
PubMed ID: 24558024
PMC ID: PMC4366593
Abstract: BACKGROUND: B-cell lymphomas are a diverse group of hematological neoplasms with differential etiology and clinical trajectories. Increased insights in the etiology and the discovery of prediagnostic markers have the potential to improve the clinical course of these neoplasms. METHODS: We investigated in a prospective study global gene expression in peripheral blood mononuclear cells of 263 incident B-cell lymphoma cases, diagnosed between 1 and 17 years after blood sample collection, and 439 controls, nested within two European cohorts. RESULTS: Our analyses identified only transcriptomic markers for specific lymphoma subtypes; few markers of multiple myeloma (N = 3), and 745 differentially expressed genes in relation to future risk of chronic lymphocytic leukemia (CLL). The strongest of these associations were consistently found in both cohorts and were related to (B-) cell signaling networks and immune system regulation pathways. CLL markers exhibited very high predictive abilities of disease onset even in cases diagnosed more than 10 years after blood collection. CONCLUSIONS: This is the first investigation on blood cell global gene expression and future risk of B-cell lymphomas. We mainly identified genes in relation to future risk of CLL that are involved in biological pathways, which appear to be mechanistically involved in CLL pathogenesis. Many but not all of the top hits we identified have been reported previously in studies based on tumor tissues, therefore suggesting that a mixture of preclinical and early disease markers can be detected several years before CLL clinical diagnosis.